- Congress continues negotiations on another economic relief package
- Electoral College vote affirms Biden's win
- FDA staff said Moderna’s (MRNA.US) Covid-19 vaccine is “highly effective”
US indices launched today's session higher as progress toward a new coronavirus-aid bill lifted market sentiment, while investors awaited new economic cues from the Federal Reserve's final meeting of the year. Yesterday House Speaker Nancy Pelosi and Treasury Secretary Steven Mnuchin discussed the bipartisan $908 billion coronavirus package. Meanwhile, coronavirus vaccination already started in the US although infections continue to increase and the death toll surpassed 300K. The most populous state California is already suffering badly, while New York is headed toward a second full shutdown if new infections and hospitalizations continue at their current pace, Governor Andrew Cuomo said Monday. The Fed is expected to maintain interest rates at near-zero during its two-day meeting and signal it will stay there for years to come. The recent coronavirus vaccine roll-out is also expected to improve the bank's 2021 outlook. Meanwhile Joe Biden on Monday won the state-by-state Electoral College vote that formally determines the U.S. presidency.
US100 – index launched today’s session higher, attempting to extend yesterday gains. Index managed to break above the major resistance at 12,500 pts which is additionally strengthened by 50 SMA (green line). If the current sentiment prevails, the upward move could be extended to the 12,669 pts handle, where all-time highs are located. Source: xStation5Moderna (MRNA.US) – US FDA announced that company's Covid-19 vaccine data meets expectations for emergency use. Such an authorization isn’t the same as a full approval, which can typically take months. Moderna, like Pfizer, has only submitted two months of follow-up safety data, but the agency usually requires six months for full approval. Separately company confirmed that some documents related to the submission of its Covid-19 vaccine candidate for European approval were accessed in a hacker attack on the European Medicines Agency, however but data on individual study participants were not disclosed.
Moderna (MRNA.US) stock launched today’s session slightly lower. Currently price is testing lower limit of the triangle formation. Should a break below occur, then another downward impulse towards support at $129.12 could be launched. On the other hand, if buyers manage to regain control then resistance at $170.42 could be at risk. Source: xStation5
Eli Lilly (LLY.US) will acquire Prevail Therapeutics for $880 million or $22.50 per share, with Prevail shareholders also receiving a “contingent value right” worth up to $4 per share subject to future regulatory approvals of Prevail drugs. Also Eli Lilly raised its quarterly dividend by 15% and provided upbeat full-year earnings forecast.
Regeneron Pharmaceuticals (REGN.US) will temporarily halt enrollment in a clinical trial for an experimental lymphoma treatment after the FDA requested changes in trial protocols.
Bristol-Myers (BMY.US) shares rose 2% in premarket after Goldman Sachs added the drugmaker’s stock to its “Conviction List”. Bank believes that number of Food and Drug Administration approvals should increase earnings estimates.
Apple (APPL.US) is planning to increase iPhone production to 96 million for the first half of 2021, according to the Nikkei Asia news which refers to a sales forecast that Apple shared with its suppliers. This would represent an increase of almost 30% over the same period in 2020.
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
